Hikal [HIKAL] vs Aarti Pharmalabs [AARTIPHARM] Detailed Stock Comparison

Hikal Ltd.

NSE
Loading...

Aarti Pharmalabs Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Hikal Ltd. wins in 6 metrics, Aarti Pharmalabs Ltd. wins in 13 metrics, with 0 ties. Aarti Pharmalabs Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Hikal Ltd. Aarti Pharmalabs Ltd. Better
P/E Ratio (TTM) 257.60 29.41 Aarti Pharmalabs Ltd.
Price-to-Book Ratio 1.83 3.07 Hikal Ltd.
Debt-to-Equity Ratio 0.57 32.97 Hikal Ltd.
PEG Ratio -1.91 -0.84 Aarti Pharmalabs Ltd.
EV/EBITDA 9.24 17.17 Hikal Ltd.
Profit Margin (TTM) 6.15% 11.87% Aarti Pharmalabs Ltd.
Operating Margin (TTM) 13.16% 17.05% Aarti Pharmalabs Ltd.
EBITDA Margin (TTM) 13.16% 17.05% Aarti Pharmalabs Ltd.
Return on Equity 7.19% 13.69% Aarti Pharmalabs Ltd.
Return on Assets (TTM) 3.59% 9.37% Aarti Pharmalabs Ltd.
Free Cash Flow (TTM) $1.43B $-1.12B Hikal Ltd.
Dividend Yield 0.49% 0.55% Aarti Pharmalabs Ltd.
1-Year Return -51.04% -27.61% Aarti Pharmalabs Ltd.
Price-to-Sales Ratio (TTM) 1.92 3.49 Hikal Ltd.
Enterprise Value $30.59B $69.01B Aarti Pharmalabs Ltd.
EV/Revenue Ratio 1.66 3.83 Hikal Ltd.
Gross Profit Margin (TTM) 52.72% 60.06% Aarti Pharmalabs Ltd.
Revenue per Share (TTM) $146 $199 Aarti Pharmalabs Ltd.
Earnings per Share (Diluted) $-1.06 $23.56 Aarti Pharmalabs Ltd.
Beta (Stock Volatility) N/A 0.11 N/A

Hikal Ltd. vs Aarti Pharmalabs Ltd. Stock Performance Analysis

Loading Price Chart...

HIKAL
AARTIPHARM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Hikal Ltd.1.77%4.16%-7.05%10.64%-25.21%-17.48%
Aarti Pharmalabs Ltd.-0.08%5.66%-9.99%1.80%-15.40%-13.91%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Hikal Ltd.-51.04%-42.23%-59.62%71.68%349.74%297.82%
Aarti Pharmalabs Ltd.-27.61%62.73%147.07%147.07%147.07%147.07%

Performance & Financial Health Analysis: Hikal Ltd. vs Aarti Pharmalabs Ltd.

MetricHIKALAARTIPHARM
Market Information
Market Cap i₹23.07B₹62.82B
Market Cap CategorySmall capMid cap
10 Day Avg. Volume i270,350147,034
90 Day Avg. Volume i394,027193,883
Last Close₹187.25₹640.65
52 Week Range₹146.25 - ₹382.30₹585.00 - ₹971.00
% from 52W High-51.02%-34.02%
All-Time High₹742.00 (Aug 16, 2021)₹971.00 (Jul 16, 2025)
% from All-Time High-74.76%-34.02%
Growth Metrics
Quarterly Revenue Growth0.37%-0.20%
Quarterly Earnings Growth0.68%-0.35%
Financial Health
Profit Margin (TTM) i0.06%0.12%
Operating Margin (TTM) i0.13%0.17%
Return on Equity (TTM) i0.07%0.14%
Debt to Equity (MRQ) i0.5732.97
Cash & Liquidity
Book Value per Share (MRQ)₹102.38₹225.70
Cash per Share (MRQ)N/A₹6.13
Operating Cash Flow (TTM) i₹1.54B₹3.51B
Levered Free Cash Flow (TTM) i₹908.00M₹2.72B
Dividends
Last 12-Month Dividend Yield i0.49%0.55%
Last 12-Month Dividend i₹1.00₹4.00

Valuation & Enterprise Metrics Analysis: Hikal Ltd. vs Aarti Pharmalabs Ltd.

MetricHIKAL (Apr 24, 2026)AARTIPHARM (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i257.6029.41
Forward P/E i23.10N/A
PEG Ratio i-1.91-0.84
Price to Sales (TTM) i1.923.49
Price to Book (MRQ) i1.833.07
Market Capitalization
Market Capitalization i₹23.07B₹62.82B
Enterprise Value i₹30.59B₹69.01B
Enterprise Value Metrics
Enterprise to Revenue i1.663.83
Enterprise to EBITDA i9.2417.17
Risk & Other Metrics
Beta iN/A0.11
Book Value per Share (MRQ) i₹102.38₹225.70

Financial Statements Comparison: Hikal Ltd. vs Aarti Pharmalabs Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricHIKAL (2025)AARTIPHARM (2025)
Revenue/Sales i18.44B20.86B
Cost of Goods Sold i8.75B12.18B
COGS % of Revenue i47.5%58.4%
Gross Profit i9.68B8.68B
Gross Margin i52.5%41.6%
Research & Development iN/A328.32M
Operating Income (EBIT) i1.95B3.77B
Operating Margin i10.6%18.1%
EBITDA i3.31B4.73B
EBITDA Margin i18.0%22.7%
Pre-Tax Income i1.24B3.61B
Pre-Tax Income % of Revenue i6.7%17.3%
Income Tax i330.00M882.85M
Income Tax % of Revenue i1.8%4.2%
Net Income (Profit) i908.00M2.72B
Profit Margin i4.9%13.1%

Balance Sheet & Liquidity Metrics

MetricHIKAL (2025)AARTIPHARM (2025)
Cash & Equivalents i130.00M67.34M
Total Current Assets i9.95B13.22B
Total Current Assets % of Revenue i54.0%63.4%
Total Current Liabilities i7.90B6.57B
Total Current Liabilities % of Revenue i42.8%31.5%
Long-Term Debt i3.70B1.23B
Long-Term Debt % of Revenue i20.0%5.9%
Total Shareholders Equity i12.62B19.90B
Retained Earnings i9.67B13.23B
Retained Earnings % of Revenue i52.5%63.4%
Property, Plant & Equipment i403.00M11.04B

Cash Flow Statement Comparison

MetricHIKAL (2025)AARTIPHARM (2025)
Operating Cash Flow i1.54B3.51B
Operating Cash Flow % of Revenue i8.4%16.8%
Capital Expenditures i-1.36B-4.02B
Free Cash Flow i1.43B-1.12B
FCF Margin i7.8%-5.4%
Debt Repayment i-1.03BN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricHIKALAARTIPHARM
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i123.30M90.66M
Float Shares i26.57M47.89M
% Held by Insiders i69.08%42.62%
% Held by Institutions i7.68%12.01%
% Held by Public i23.24%45.37%

Dividend Analysis & Yield Comparison: Hikal Ltd. vs Aarti Pharmalabs Ltd.

MetricHIKALAARTIPHARM
Last 12-Month Dividend i₹1.00₹4.00
Last 12-Month Dividend Yield i0.49%0.55%
3-Year Avg Annual Dividend i₹1.13₹3.17
3-Year Avg Dividend Yield i0.19%0.27%
3-Year Total Dividends i₹3.40₹9.50
Ex-Dividend DateFeb 17, 2026Feb 16, 2026